Close X
Friday, November 1, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

Officials face battle of confidence in AstraZeneca

Officials face battle of confidence in AstraZeneca
Infectious disease doctor Zain Chagla says it's an important message, but confusing for Canadians as Germany and other European countries move to limit the vaccine's use while they investigate reports of blood clots emerging after some inoculations.

Officials face battle of confidence in AstraZeneca

Canada and Germany ink deal on green energy

Canada and Germany ink deal on green energy
The two countries might not see fully eye to eye on hydrogen, with Canada focusing recentlyon so-called "blue hydrogen."

Canada and Germany ink deal on green energy

First-degree murder charge in school attack

First-degree murder charge in school attack
Police said a 17-year-old female student was violently assaulted Monday morning in a classroom at Christ the King School in Leduc, just south of Edmonton.

First-degree murder charge in school attack

Edward John ordered to stand trial on sex charges

Edward John ordered to stand trial on sex charges
The BC Prosecution Service confirmed the charges against Edward John will go forward after a preliminary hearing wrapped up last week.

Edward John ordered to stand trial on sex charges

TSB to further probe deadly B.C. tug sinking

TSB to further probe deadly B.C. tug sinking
Two men died and one survived when the Ingenika sank Feb. 11 south of Kitimat while towing a barge, which remained afloat.

TSB to further probe deadly B.C. tug sinking

1506 new cases over 3 days

1506 new cases over 3 days
The province is targeting indoor religious gatherings by April. Details will come soon according to Dr. Henry.

1506 new cases over 3 days